N/A
N=4,461
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
Aedes-borne Diseases · Dengue · Chikungunya · Zika
Bottom Line
View on ClinicalTrials.gov: NCT04343521 ↗Enrolled (actual)
4,461
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically — 213; 209; 151; 146 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Targeted Indoor Residual Spraying (TIRS) (Other)
- Age
- Pediatric · 2+ yrs
- Sex
- All
- Sponsor
- Emory University
- Primary completion
- Apr 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically |
213; 209; 151; 146; 1; 0 | — |
| SECONDARY Number Positive Tests of Laboratory Confirmed Aedes-borne Viruses Infections By Season |
36; 39; 216; 166; 169; 204 | — |
| SECONDARY Ae. Aegypti Mosquito Infection Rate With Aedes-borne Viruses (DENV, CHIKV and ZIKV) |
0; 0 | — |
| SECONDARY Ae. Aegypti Indoor Entomological Index of Adult Mosquito Abundance |
0.61; 1.39 | — |
| SECONDARY Ae. Aegypti Indoor Entomological Index of Female Mosquito Abundance |
0.29; 0.65 | — |
| SECONDARY Ae. Aegypti Indoor Entomological Index of Bloodfed Female Mosquito Abundance |
0.25; 0.53 | — |
| SECONDARY Number of Households Where the Head of Household Would Recommend the Intervention |
2160 | — |
| SECONDARY Number of Households With a Resident That Had a Reaction to the Insecticide |
2 | — |
Summary
The objective of this trial is evaluate the efficacy of Targeted Indoor Residual Spraying (TIRS) in preventing symptomatic disease caused by Aedes-borne diseases (ABDs) in children 2 to 15 years of age in the city of Merida, Yucatan State, Mexico.
Eligibility Criteria
Inclusion Criteria
Household Level Inclusion Criteria:
- Household is located within the bounds of a study cluster (5x5 city-block clusters)
- City block has at least 60% premises that are residential
Individual Level Inclusion Criteria:
- 2 or more and up to 15 years of age at the time of initial enrollment
- Living in a house that consented to TIRS (for children in TIRS cluster)
Exclusion Criteria
Household Level Exclusion Criteria:
- Households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile)
- Sites where no residents spend time during the day (i.e. work 7days a week outside the home)
- Inability for a resident to provide informed consent
- Non-residential places (e.g., businesses, schools, markets, etc.)
Individual Level Exclusion Criteria:
- Less than 2 years of age or more than 15 years of age at the time of enrollment
- Not living in a house that consented to TIRS (for children in TIRS cluster)
- Having a medical condition that prevents implementation of study procedures
- Temporary visitor to household
- Plans to leave study area within next 12 months
Data sourced from ClinicalTrials.gov (NCT04343521). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.